Needham & Company LLC Reaffirms “Buy” Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Needham & Company LLC reaffirmed their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has a $207.00 target price on the specialty pharmaceutical company’s stock.

A number of other brokerages have also recently commented on JAZZ. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. TD Cowen cut their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Cantor Fitzgerald reiterated an “overweight” rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Robert W. Baird upped their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $163.00 price objective (down previously from $166.00) on shares of Jazz Pharmaceuticals in a research report on Thursday. Three research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $175.33.

Jazz Pharmaceuticals Trading Up 4.9 %

JAZZ opened at $125.10 on Thursday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $134.17. The stock has a market cap of $7.56 billion, a PE ratio of 17.62, a PEG ratio of 0.98 and a beta of 0.57. The business has a 50 day moving average of $113.29 and a 200-day moving average of $110.62.

Insiders Place Their Bets

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. The trade was a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the transaction, the chief executive officer now directly owns 428,976 shares in the company, valued at $47,547,699.84. This trade represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,110 shares of company stock valued at $720,160. Insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of JAZZ. Vanguard Group Inc. raised its position in shares of Jazz Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock valued at $776,551,000 after buying an additional 84,941 shares during the last quarter. LSV Asset Management grew its stake in Jazz Pharmaceuticals by 4.2% during the second quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company’s stock valued at $264,750,000 after acquiring an additional 99,705 shares in the last quarter. Pacer Advisors Inc. increased its holdings in Jazz Pharmaceuticals by 15.3% in the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after acquiring an additional 278,465 shares during the last quarter. Capital World Investors purchased a new stake in Jazz Pharmaceuticals in the 1st quarter worth $171,943,000. Finally, Baupost Group LLC MA boosted its holdings in shares of Jazz Pharmaceuticals by 52.8% during the 2nd quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock valued at $136,000,000 after purchasing an additional 440,552 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.